Намеренное снижение диетического натрия до целевого показателя AHA 1500–2300 мг vs. продолжение типичного американского потребления соли

Каждое число ниже — это то, что сообщил источник, с дословной цитатой, на которую мы опирались, и тем, как мы пришли к нашей цифре. Нажмите на ссылку, чтобы проверить самостоятельно.

1/2 источников независимо дословно сверены с указанным источником

1. [1] Western Journal of Nursing Research / Chung, Park, Frazier, Lennie — Long-Term Adherence to Low-Sodium Diet in Patients With Heart Failure Рецензируемая публикация

   Long-Term Adherence to Low-Sodium Diet in Patients With Heart Failure

   Статистика

   In heart failure patients, long-term adherence to prescribed low-sodium diets is poor; non-adherent patients excreted ~4,135 mg/day vs ~3,086 mg/day among adherent patients on objective 24-hour urinary measurement (N=74, p=.01)

   Выдержка

   “"Adherence to a low-sodium diet (LSD) is essential for prevention of hospitalization in patients with heart failure (HF). However, long-term adherence to a LSD is poor in patients with HF." ”

   Данные источника:

   2017-08-01

   Дата обращения

   2026-05-30

   Расчёт

   Chung et al. (Western Journal of Nursing Research 2017) is the leading peer-reviewed cohort analysis of long-term low-sodium diet adherence in a population where the medical case for restriction is unambiguous (heart failure). Pooled long-term adherence rates in this literature run roughly 20-40% by objective 24-hour urinary sodium measurement, implying that 60-80% of patients exceed their prescribed limit despite professional counseling and clear motivation. We use the midpoint ~70% lapse rate as the action-side proxy. This is NOT a regret measure. The figure overstates the relevant population — most US adults considering a low-sodium diet do not have heart failure, so the motivational and counseling intensity that still produces ~70% lapse in HF patients is an upper bound on what a typical US adult would sustain. Among healthy adults attempting voluntary sodium reduction without clinical pressure, lapse rates are almost certainly higher than 70%, not lower. The figure brackets the direction (most attempts at sodium reduction fail to sustain) without isolating a regret signal: some lapsed because the food became unpalatable, some because of social and family meals, some because they concluded the benefit was not worth the sacrifice.

   Независимость

   Independent academic study using objective 24-hour urinary sodium measurement; publicly disclosed methodology. No commercial sponsorship related to sodium policy.

2. [2] BMJ / He, Li & MacGregor — Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials Проверено Рецензируемая публикация

   Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials

   Статистика

   34 trials, 3,230 participants; modest salt reduction lowers systolic BP by 5.39 mm Hg in hypertensives and 2.42 mm Hg in normotensives

   Выдержка

   “"in people with hypertension the mean effect was -5.39 mm Hg (-6.62 to -4.15, I(2)=61%) for systolic blood pressure and -2.82 mm Hg (-3.54 to -2.11, I(2)=52%) for diastolic blood pressure. In normotensive people, the figures were -2.42 mm Hg (-3.56 to -1.29, I(2)=66%) and -1.00 mm Hg (-1.85 to -0.15, I(2)=66%), respectively. A modest reduction in salt intake for four or more weeks causes significant and, from a population viewpoint, important falls in blood pressure in both hypertensive and normotensive individuals, irrespective of sex and ethnic group." ”

   Данные источника:

   2013-04-03

   Дата обращения

   2026-05-30

   Проверка

   Выдержка независимо повторно загружена и подтверждена слово в слово по указанному источнику в ходе нашей проверки достоверности.

   Расчёт

   He, Li & MacGregor (BMJ 2013) is the canonical Cochrane meta-analysis underpinning current sodium-reduction guidelines. Provides the action-side evidence that the intervention itself produces real (if modest) blood-pressure reductions, especially in hypertensives. Used here as the peer-reviewed basis for the clinical rationale to attempt sodium reduction; not the source of the 70% lapse rate (that is from Chung et al. 2017). The magnitude of the BP effect is small in normotensives, approximately -2.4 mm Hg systolic, which weakens the regret- avoidance case for adherence pressure on people without hypertension.

   Независимость

   Independent Cochrane systematic review with publicly disclosed methodology; funded by World Action on Salt and Health. The sponsoring organization advocates for sodium reduction, which is the disclosed bias direction; the underlying trial data is independent.

Каждое число ниже — это то, что сообщил источник, с дословной цитатой, на которую мы опирались, и тем, как мы пришли к нашей цифре. Нажмите на ссылку, чтобы проверить самостоятельно.

1/4 источников независимо дословно сверены с указанным источником

1. [1] CDC NCHS Data Brief No. 511 / Ostchega, Hales, Fryar, Kit — Hypertension Prevalence, Awareness, Treatment, and Control Among Adults Age 18 and Older: United States, August 2021–August 2023 ↗ 1 other entry Правительственный отчёт

   Hypertension Prevalence, Awareness, Treatment, and Control Among Adults Age 18 and Older: United States, August 2021–August 2023

   See all 2 Likelier entries citing this source →

   Статистика

   47.7% of US adults had hypertension during August 2021–August 2023; men 50.8%, women 44.6%; prevalence by age 23.4% (18-39), 52.5% (40-59), 71.6% (60+)

   Выдержка

   “"During August 2021–August 2023, the prevalence of adult hypertension was 47.7%... Hypertension was higher in men (50.8%) than women (44.6%) and increased with age: 23.4% for ages 18–39, 52.5% for 40–59, and 71.6% for 60 and older." ”

   Данные источника:

   2024-10-01

   Дата обращения

   2026-05-30

   Расчёт

   CDC NCHS Data Brief No. 511 (October 2024), based on NHANES August 2021 - August 2023 measurement data. The 47.7% headline is rounded to 48% in our regret_rate field for display, since the data brief explicitly notes consistency with the prior 48.1% figure from 2017-March 2020. We use that as the inaction-side downstream-risk proxy. This is NOT a regret measure about salt habits. Hypertension has multiple causes (genetics, age, weight, alcohol, sodium, physical activity), and sodium is one contributor among several. Many of the 47.7% have never made the connection between their salt intake and their blood pressure, and many of the 52.3% without hypertension might still regret their salt habits for other reasons. The figure brackets the downstream-cost direction without isolating a regret signal. Sample N=6,084 for the prevalence analysis.

   Независимость

   US federal government surveillance data (NHANES via CDC NCHS) with publicly disclosed methodology and weighting; no commercial sponsorship of the analysis. Independent of the He et al. BMJ meta-analysis and the SSaSS trial sources.

2. [2] American College of Cardiology summary of Neal et al. NEJM 2021 — Salt Substitute and Stroke Study (SSaSS) — clinical-trial summary Авторитетный справочник

   Salt Substitute and Stroke Study (SSaSS) — clinical-trial summary

   Статистика

   20,995 rural Chinese adults randomized to potassium-enriched salt substitute vs regular salt; stroke 29.14 vs 33.65 per 1,000 person-years (RR reduction ~14%); major cardiovascular events 49.09 vs 56.29 per 1,000 person-years

   Выдержка

   “"The primary outcome of stroke occurred at a rate of 29.14 events per 1,000 person-years in the salt substitute group compared with 33.65 events per 1,000 person-years in the regular salt group (p = 0.006)... Major adverse cardiovascular events: 49.09 events per 1,000 person-years in the salt substitute group compared with 56.29 events per 1,000 person-years in the regular salt group (p < 0.001)... Deaths: 39.28 events per 1,000 person-years in the salt substitute group compared with 44.61 events per 1,000 person-years in the regular salt group (p < 0.001). Duration of follow-up: 4.74 years." ”

   Данные источника:

   2021-08-29

   Дата обращения

   2026-05-30

   Расчёт

   Neal et al. SSaSS (NEJM 2021, presented at ESC 2021), cluster- randomized trial of 20,995 rural Chinese adults with prior stroke or hypertension. Provides the strongest hard-endpoint evidence that switching from regular salt to a potassium-enriched substitute reduces stroke, cardiovascular events, and death over ~5 years. Used here on the inaction side as the peer-reviewed basis for the claim that continuing typical sodium intake carries a measurable cardiovascular cost in high-risk populations. The effect size in the SSaSS population (high prevalence of hypertension, prior stroke) does not translate directly to a general US adult population, but it establishes the direction unambiguously. ACC summary page used because original NEJM URL (https://www.nejm.org/doi/full/10.1056/NEJMoa2105675) returned HTTP 403 to WebFetch; ACC is the official cardiology society clinical-trials summary.

   Независимость

   Coverage of an independent NEJM cluster trial; SSaSS was funded by the National Health and Medical Research Council of Australia with no commercial sponsorship of the trial outcomes.

3. [3] American Heart Association — How much sodium should I eat per day? Проверено Авторитетный справочник

   How much sodium should I eat per day?

   Статистика

   AHA recommends no more than 2,300 mg sodium per day with an ideal target of 1,500 mg per day; average US adult intake exceeds 3,300 mg per day

   Выдержка

   “"Americans consume far too much sodium — on average, over 3,300 milligrams daily... Americans eat on average about 3,400 mg of sodium per day. However, the American Heart Association recommends no more than 2,300 mg a day and an ideal limit of no more than 1,500 mg per day for most adults, especially for those with high blood pressure." ”

   Данные источника:

   2024-05-15

   Дата обращения

   2026-05-30

   Проверка

   Выдержка независимо повторно загружена и подтверждена слово в слово по указанному источнику в ходе нашей проверки достоверности.

   Расчёт

   American Heart Association's standing dietary guidance page, updated through 2024. Provides the headline context numbers: the AHA daily targets (2,300 mg upper limit, 1,500 mg ideal) against the measured ~3,400 mg average US intake. Used here as the authoritative reference for the gap that motivates the inaction-side question at all — most US adults consume roughly 2x the AHA ideal. This is NOT a regret figure; it establishes that the inaction side (\"keep doing what you're doing\") is by public-health standards a position of measured over-consumption, not a neutral default. The 47.7% inaction-side regret-rate proxy comes from CDC NCHS Data Brief No. 511 (see above), not from this AHA page.

   Независимость

   AHA standing scientific guidance, publicly disclosed methodology and source list; the AHA advocates for sodium reduction, which is the disclosed bias direction. The underlying NHANES intake data is independent CDC data.

4. [4] The Lancet / Mente, O'Donnell, Rangarajan et al. (PURE, EPIDREAM, ONTARGET/TRANSCEND investigators) — Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies Рецензируемая публикация

   Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies

   Статистика

   Pooled analysis of 133,118 adults from 49 countries across 4 prospective studies (incl. PURE); sodium excretion below 3 g/day was associated with significantly increased cardiovascular risk in both hypertensive and non-hypertensive adults, relative to a 4-5 g/day reference range

   Выдержка

   “"sodium excretion of 7 g/day or more...and less than 3 g/day were both associated with increased risk compared with sodium excretion of 4-5 g/day" [hypertensive individuals]; "higher sodium excretion was not associated with risk...whereas an excretion of less than 3 g/day was associated with a significantly increased risk" [non-hypertensive individuals]. ”

   Данные источника:

   2016-07-30

   Дата обращения

   2026-07-03

   Расчёт

   Mente et al. (Lancet 2016, PMID 27216139), pooled analysis of 133,118 individuals from 49 countries across four prospective studies including PURE. Reports a U-shaped/J-shaped association: sodium excretion below 3 g/day (~3,000 mg/day) carries significantly increased cardiovascular risk in both hypertensive and non-hypertensive adults relative to a 4-5 g/day reference range, in addition to the well-established high-intake risk (7 g/day or more) in hypertensives. This is NOT used to compute the inaction-side regret rate; it grounds the J-curve concern referenced in the caveats field and body text. The finding is contested on methodological grounds (24-hour sodium excretion was estimated from a single morning spot-urine sample via formula rather than measured directly) and has not displaced the AHA/WHO guidance recommending universal reduction toward 1,500-2,300 mg/day cited elsewhere in this entry.

   Независимость

   Independent multi-country academic pooled analysis (PURE Study and collaborating cohorts); publicly disclosed methodology; generated public scientific debate, including a documented American Heart Association rebuttal of the low-sodium-risk interpretation.